Lilly buys Centessa for up to $7.8B to build neuroscience pipeline beyond obesity
What's the deal? Eli LillyDealroom has a profile for this one. Try Dealroom → has agreed to acquire UK and Boston-headquartered Centessa Pharmaceuticals for approximately $6.3 billion upfront, with potential additional payments of up to $1.5 billion tied to regulatory milestones — bringing the total deal value to $7.8 billion.
The offer represents a 70% premium to Centessa's closing price on March 30, 2026. The deal is expected to close in the third quarter of 2026 and is Lilly's largest acquisition since its $8 billion purchase of Loxo Oncology in 2019.
Centessa, publicly launched in 2021, has narrowed its focus to sleep-wake disorders. Its lead drug, cleminorexton, has been tested in Phase 2 studies for narcolepsy and idiopathic hypersomnia — conditions that leave patients struggling to stay awake during the day. The company's drugs work by targeting orexin receptors in the brain, a mechanism that also holds potential for treating fatigue associated with Alzheimer's disease and depression. Centessa has no approved drugs.
Why now? Lilly is one of the world's most valuable companies on the back of its blockbuster obesity and diabetes drugs Mounjaro and Zepbound, but their patents will eventually expire.
Lilly's neuroscience president Carole HoDealroom has a profile for this one. Try Dealroom → framed the deal as an opportunity to pursue orexin-based treatments at the speed and scale that Centessa could not achieve independently. Lilly already has a toehold in sleep: Zepbound is the only approved drug for sleep apnoea, a condition affecting more than 23 million American adults.
What could go wrong? Centessa has no approved drugs and its lead candidate is still in Phase 2 — meaning Lilly is paying a significant premium for clinical-stage assets with meaningful development and regulatory risk still ahead.
Centessa is also behind competitors: TakedaDealroom has a profile for this one. Try Dealroom → has already submitted an orexin agonist for narcolepsy to regulators, and AlkermesDealroom has a profile for this one. Try Dealroom → plans to begin a Phase 3 programme for its narcolepsy drug in 2026. If cleminorexton fails in later-stage trials, Lilly will have paid $6.3 billion upfront for little.
The signal: Lilly's acquisition is the latest sign that the GLP-1 era is prompting the industry's biggest players to aggressively diversify before the inevitable patent cliff arrives.
Neuroscience — and sleep disorders in particular — is emerging as a strategic priority: a large, underserved market where existing treatments are poor and new mechanisms like orexin agonism offer genuine differentiation. For Lilly, buying Centessa is as much about securing a platform for a range of future neuroscience indications as it is about narcolepsy alone.
Sources:
Eli Lilly
Centessa Pharmaceuticals
Reuters
CNBC
BioSpace
Fierce Biotech
Morningstar
Stat News
Bloomberg
J.V.
